Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 17/20 | 0.39 |
| ▸ | CA1 | P00915 | 17/20 | 0.39 |
| ▸ | CA2 | P00918 | 17/20 | 0.39 |
| ▸ | CA4 | P22748 | 12/20 | 0.39 |
| ▸ | CA9 | Q16790 | 10/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.36 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912981 | 0.93 | DAGLA (0.40) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL653132 | 0.92 | C5AR1 (0.40) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL648222 | 0.91 | C5AR1 (0.43) | C5AR1MEP1B | |
| SCHEMBL649414 | 0.91 | CA2 (0.41) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL648790 | 0.91 | C5AR1 (0.43) | C5AR1DAGLAMEP1B | |
| SCHEMBL648462 | 0.90 | CA1 (0.42) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL650095 | 0.89 | C5AR1 (0.39) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL650071 | 0.89 | C5AR1 (0.37) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL649804 | 0.89 | C5AR1 (0.39) | C5AR1CA12CA1CA2CA4 | |
| SCHEMBL649537 | 0.89 | C5AR1 (0.38) | C5AR1CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |